Transsexualism and osteoporosis

Area of Science:

• Endocrinology
• Bone Metabolism
• Transgender Health

Background:

• Osteoporosis is a significant concern, particularly in individuals undergoing hormone therapies.
• Understanding the effects of cross-gender hormone replacement therapy (HRT) on bone health is crucial for transsexual patients.

Purpose of the Study:

• To investigate the influence of cross-gender hormone replacement therapy on osteoporosis development in transsexual individuals.
• To assess bone density changes in male-to-female and female-to-male transsexual patients undergoing long-term HRT.

Main Methods:

• Comparative analysis of bone mineral density (BMD) in transsexual patients receiving cross-gender HRT versus their biological sex.
• Longitudinal monitoring of BMD in two groups: 10 male-to-female and 10 female-to-male transsexual patients.
• Evaluation of BMD variability independent of age and direction of gender transition.

Main Results:

• No significant differences in bone density were observed between cross-gender HRT-treated transsexual groups and their respective biological sex controls.
• Bone density exhibited minimal variability throughout long-term HRT.
• BMD stability was consistent across different ages and transition directions (male-to-female and female-to-male).

Conclusions:

• Long-term cross-gender hormone replacement therapy in transsexual patients is associated with a low risk of developing osteoporosis.
• Current HRT regimens appear to maintain bone health effectively in this population.
• Bone density remains stable, irrespective of the direction of gender transition or patient age.